Noriyoshi Iriyama

16PUBLICATIONS
30CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Aug 14, 2026
ELTS Score and Early "Warning" Define a Two-Stage Risk Framework for Failure-Free Survival in Chronic-Phase CML.

|Jul 09, 2026
Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukaemia in the chronic phase: Result of the Japan Adult Leukemia Study Group RE-STOP219 study.

|Jun 18, 2026
Treatment-Free Remission and Immune Profiling after Frontline Second-Generation TKI Therapy in CML.

|Jun 11, 2026
Early predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIs.

|Nov 09, 2025
Favorable response to daratumumab combination therapy in patients with multiple myeloma with an immature phenotype: a report from the J-CHARGE study group.

Noriyoshi Iriyama, Hitomi Nakayama, Masaru Nakagawa

|Jul 25, 2024
A Higher Neutrophil Count Is Associated with Favorable Achievement of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Who Received Second Generation Tyrosine Kinase Inhibitor as Frontline Treatment.

Hiroshi Ureshino, Yusuke Takeda, Kazuharu Kamachi

Pageof 3

Frequent Collaborators

5 joint publications

Emiko Sakaida

5 joint publications

Naoto Takahashi

4 joint publications

Takaaki Ono

4 joint publications

Hitoshi Kiyoi